Moderna Stock Current Valuation
| MRNA Stock | USD 43.06 0.33 0.76% |
Valuation analysis of Moderna helps investors to measure Moderna's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 35.2 B, whereas Enterprise Value Over EBITDA is forecasted to decline to (11.62). Fundamental drivers impacting Moderna's valuation include:
Price Book 1.4 | Enterprise Value 11.2 B | Enterprise Value Ebitda 4.6412 | Price Sales 3.2612 | Forward PE 32.4675 |
Undervalued
Today
Please note that Moderna's price fluctuation is very steady at this time. Calculation of the real value of Moderna is based on 3 months time horizon. Increasing Moderna's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Moderna is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moderna Stock. However, Moderna's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 43.06 | Real 73.24 | Target 167.65 | Hype 44.46 | Naive 48.77 |
The real value of Moderna Stock, also known as its intrinsic value, is the underlying worth of Moderna Company, which is reflected in its stock price. It is based on Moderna's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Moderna's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Moderna helps investors to forecast how Moderna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moderna more accurately as focusing exclusively on Moderna's fundamentals will not take into account other important factors: Moderna Company Current Valuation Analysis
Moderna's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Moderna Current Valuation | 11.19 B |
Most of Moderna's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Moderna Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Moderna is extremely important. It helps to project a fair market value of Moderna Stock properly, considering its historical fundamentals such as Current Valuation. Since Moderna's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moderna's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moderna's interrelated accounts and indicators.
Click cells to compare fundamentals
Moderna Current Valuation Historical Pattern
Today, most investors in Moderna Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moderna's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moderna current valuation as a starting point in their analysis.
Moderna Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Moderna has a Current Valuation of 11.19 B. This is 22.13% lower than that of the Biotechnology sector and 140.78% higher than that of the Health Care industry. The current valuation for all United States stocks is 32.72% higher than that of the company.
Moderna Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moderna's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moderna could also be used in its relative valuation, which is a method of valuing Moderna by comparing valuation metrics of similar companies.Moderna is currently under evaluation in current valuation category among its peers.
Moderna Current Valuation Drivers
We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 6.9B | 580.2M | 6.2B | 37.2B | 33.5B | 35.2B |
Moderna ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Moderna's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Moderna's managers, analysts, and investors.Environmental | Governance | Social |
Moderna Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 11.19 B | ||||
| Shares Outstanding | 384.82 M | ||||
| Shares Owned By Insiders | 9.52 % | ||||
| Shares Owned By Institutions | 71.60 % | ||||
| Number Of Shares Shorted | 39.86 M | ||||
| Price To Earning | 6.37 X | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 3.26 X | ||||
| Revenue | 6.85 B | ||||
| Gross Profit | 10.55 B | ||||
| EBITDA | (3.28 B) | ||||
| Net Income | (4.71 B) | ||||
| Cash And Equivalents | 8.35 B | ||||
| Cash Per Share | 21.73 X | ||||
| Total Debt | 1.24 B | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 2.10 X | ||||
| Book Value Per Share | 30.98 X | ||||
| Cash Flow From Operations | (3.12 B) | ||||
| Short Ratio | 5.12 X | ||||
| Earnings Per Share | (5.81) X | ||||
| Target Price | 76.36 | ||||
| Number Of Employees | 5.6 K | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 16.57 B | ||||
| Total Asset | 18.43 B | ||||
| Retained Earnings | 13.61 B | ||||
| Working Capital | 7.31 B | ||||
| Current Asset | 850 K | ||||
| Current Liabilities | 2.44 M | ||||
| Net Asset | 18.43 B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Moderna Piotroski F Score and Moderna Altman Z Score analysis. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.